Incannex Healthcare Inc. - 8-K Filing
Incannex Healthcare begins participant screening in DReAMzz Phase 2 study of IHL-42X for obstructive sleep apnea, with FDA Fast Track designation and prior positive Phase 2 data showing up to 83% reduction in AHI. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $IXHL